IDOR-1117-2520

IDOR-1117-2520 is a highly selective, insurmountable, orally available small molecule antagonist of the chemokine receptor CCR6, developed by Idorsia, currently in phase 1 clinical development for the treatment of immune-mediated and Th17-driven autoimmune dermatological disorders, principally psoriasis. By inhibiting CCR6, it blocks the migration of CCR6+ pathogenic T17 cells (including Th17) into inflamed tissues, disrupting the CCL20-CCR6 chemokine axis and modulating key inflammatory pathways, including those involving IL-17 and IL-23. Efficacy studies in animal models of psoriasis and nonclinical data suggest a potent impact comparable to IL-17 and IL-23 inhibitors, thus targeting both the underlying cell trafficking and broader inflammatory processes relevant to diseases like psoriasis and potentially other autoimmune conditions. IDOR-1117-2520 was selected for clinical development following optimization for reduced cytotoxicity, phototoxicity, and risk of hERG inhibition, yielding favorable ADMET and pharmacological properties[1][2][3][5][6][7][8][9].